BOX WARNING
Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of Surmontil or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Surmontil is not approved for use in pediatric patients. (See Warnings: Clinical Worsening and Suicide Risk, Precautions: Information for Patients, and Precautions: Pediatric Use)
|
| |
SURMONTIL SUMMARY
Surmontil is an antidepressant with an anxiety-reducing sedative component to its action.
Surmontil is indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression.
|
|
NEWS HIGHLIGHTSMedia Articles Related to Surmontil (Trimipramine)
Depression Doubles Risk Of Stroke In Middle-Aged Women
Source: Health News from Medical News Today [2013.05.18]
Depression doubles the risk of having a stroke in middle-aged women, according to a new study in Stroke: Journal of the American Heart Association. The research, a 12-year examination of 10,547 Australian females between the ages of 47 and 52 years old, showed that depressed women had a 2.4 times higher likelihood of stroke than those who were not suffering from depression. After adjusting for factors known to increase stroke risks, results showed that depressed women were still 1.9 times more likely to experience a stroke. Study author Caroline Jackson, Ph.D...
Screening for Depression Lacks Strong Evidence (CME/CE)
Source: MedPageToday.com - medical news plus CME for physicians [2013.05.17]
(MedPage Today) -- Primary care physicians don't need to regularly screen asymptomatic adults for depression, according to new recommendations from the Canadian Task Force on Preventive Health Care.
Adult Children of Substance Abusers More Prone to Depression
Source: MedicineNet Alcohol Abuse and Alcoholism Specialty [2013.05.17]
Title: Adult Children of Substance Abusers More Prone to Depression
Category: Health News
Created: 5/16/2013 6:36:00 PM
Last Editorial Review: 5/17/2013 12:00:00 AM
Anti-Gay Bullying Tied to Teen Depression, Suicide
Source: MedicineNet Depression Specialty [2013.05.17]
Title: Anti-Gay Bullying Tied to Teen Depression, Suicide
Category: Health News
Created: 5/16/2013 4:36:00 PM
Last Editorial Review: 5/17/2013 12:00:00 AM
Depression May Boost Stroke Risk in Middle-Aged Women, Too
Source: MedicineNet Depression Specialty [2013.05.17]
Title: Depression May Boost Stroke Risk in Middle-Aged Women, Too
Category: Health News
Created: 5/16/2013 4:36:00 PM
Last Editorial Review: 5/17/2013 12:00:00 AM
Published Studies Related to Surmontil (Trimipramine)
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol--a double-blind multicenter trial. [2009.04]
BACKGROUND: Patients with delusional depression are difficult to treat. The atypical antidepressant trimipramine was effective in a previous 4-week open label pilot study in patients with this disorder. The major neurobiological effect of trimipramine is the inhibition of the hypothalamic-pituitary-adrenocortical (HPA) system. In delusional depression HPA overactivity is more distinct than in other subtypes of depression. HPA suppression is thought to contribute to the action of trimipramine... CONCLUSION: In all, trimipramine monotherapy appears to be an effective treatment in delusional depression.
Outcome in delusional depression comparing trimipramine monotherapy with a combination of amitriptyline and haloperidol - A double-blind multicenter trial. [2008.11.25]
BACKGROUND: Patients with delusional depression are difficult to treat. The atypical antidepressant trimipramine was effective in a previous 4-week open label pilot study in patients with this disorder. The major neurobiological effect of trimipramine is the inhibition of the hypothalamic-pituitary-adrenocortical (HPA) system. In delusional depression HPA overactivity is more distinct than in other subtypes of depression. HPA suppression is thought to contribute to the action of trimipramine... CONCLUSION: In all, trimipramine monotherapy appears to be an effective treatment in delusional depression.
Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. [2005.01]
CONCLUSION: These findings suggest that fluoxetine and trimipramine are comparable in terms of efficacy and tolerability in the treatment of major depression in geriatric patients.
Antipsychotic efficacy of the antidepressant trimipramine: a randomized, double-blind comparison with the phenothiazine perazine. [2003.03]
CONCLUSION: Trimipramine failed to exhibit therapeutic equivalence to perazine in the dosages used. However, there was evidence of a substantial antipsychotic effect of trimipramine. It may be a useful medication if depressive symptoms in psychotic patients require antidepressant treatment or if other antipsychotics cannot be administered.
Differential effects of trimipramine and fluoxetine on sleep in geriatric depression. [2001.03]
The effects of trimipramine, a tricyclic antidepressant (TCA) with atypical pharmacological properties, and fluoxetine, a selective serotonine reuptake inhibitor (SSRI), were compared in an exploratory analysis using mood and polysomnographic parameters during a six-week double-blind trial in 19 depressed geriatric patients.
Clinical Trials Related to Surmontil (Trimipramine)
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Recruiting]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
treatments.
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
antidepressant treatments.
Reports of Suspected Surmontil (Trimipramine) Side Effects
Rhabdomyolysis (4),
Renal Failure Acute (4),
Delirium (4),
Confusional State (3),
Therapeutic Response Increased (3),
Disorientation (3),
Medication Error (3),
Hyponatraemia (3),
Tremor (3),
Drug Interaction (2), more >>
|
|
|
|
Page last updated: 2013-05-18
|
